A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: An Egyptian experience

International Urology and Nephrology

Volumn 41, Issue 1, 2009, Pages 153-161

  Sabry, Alaa ^a,b   Abo Zenah, Hamdy ^c   Medhat, Tarek ^a   Sheashaa, Hussein ^a   Mahmoud, Khaled ^a   El Huseini, Amr ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

^c MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Cyclophosphamide; Fortnightly; Lupus nephritis

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; MESNA; PREDNISONE;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLADDER DISEASE; CELLULITIS; CHEST INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EGYPT; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERTENSION; INFECTION; KIDNEY BIOPSY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MULTIPLE CYCLE TREATMENT; PNEUMONIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SURVIVAL; UNSPECIFIED SIDE EFFECT;

ADULT; CYCLOPHOSPHAMIDE; EGYPT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; PROSPECTIVE STUDIES; PULSE THERAPY, DRUG; REMISSION INDUCTION;

EID: 62349098812     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-007-9325-4     Document Type: Article

References (38)

1. Ferrantelli A, Bono L, Tortorici C, Termini R, Giammarresi C, Rotolo U (2005) Treatment of lupus nephritis. G Ital Nefrol 22:S27-S33
2. Tahir H, Isenberg DA (2005) Novel therapies in lupus nephritis. Lupus 14:77-82
3. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC (2004) Treatment for lupus nephritis. Cochrane Database Syst Rev (1):CD002922
4. Ponticelli C (1997) Treatment of lupus nephritis - the advantages of a flexible approach. Nephrol Dial Transplant 12:2057-2059
5. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D (1987) Long-term follow-up of patients with lupus nephritis: A study based on the classification of the World Health Organization. Am J Med 83:877-885
6. Boumpas DT, Austin HA III, Vaughn EM, et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741-745
7. Lehman TJ, Onel K (2000) Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus. J Pediatr 136(2):243-247
8. Dooley MA, Hogan S, Jennette C, Falk R (1997) Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Glomerular disease collaborative network. Kidney Int 51:1188-1195
9. Bono L, Cameron JS, Hicks JA (1999) The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 92:211-218
10. Urowitz MB (1993) Is "aggressive" therapy necessary for systemic lupus erythematosus? Rheum Dis Clin North Am 19:263-270
11. Bansal VK, Beto JA (1997) Treatment of lupus nephritis: A meta-analysis of clinical trials. Am J Kidney Dis 29:193-199
12. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119:366-369
13. Gourley MF, Austin HA III, Scott D, et al (1996) Methylprednisolone and cyclophosphamide alone or in combination in patients with lupus nephritis: A randomized controlled trial. Ann Intern Med 125:549-557
14. D'Cruz D, Cuadrado MJ, Mujic F, Tungekar MF, Taub N, Lloyd M, et al (1997) Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 15:275-282
15. McCune WJ (2005) Mycophenolate mofetil for lupus nephritis. N Engl J Med 353:2282-2284
16. Ponticelli C (1997) Treatment of lupus nephritis-the advantages of a flexible approach. Nephrol Dial Transplant 12:2057-2059
17. Wright JT Jr, Agodoa L, Contreras G, et al (2002) Successful blood pressure control in the african american study of kidney disease and hypertension. Arch Intern Med 162: 1636-1643
18. Peterson JC, Adler S, Bukart JM, Greene T, Hebert LA, et al (1995) For the Modification of Diet in Renal Disease (MDRD) study group. Blood pressure control, proteinuria and the progression of renal disease. Ann Intern Med 123:754-762
19. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL (1986) Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 14:614-619
20. Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone alone. Arthritis Rheum 34:945-950
21. Lehman TJA, Sherry DD, Wagner-Weiner L, McCurdy DK, Emery HM, Magilavy DB, et al (1989) Intermittent intravenous cyclophosphamide for lupus nephritis. J Pediatr 114:1055-1060
22. Petri M, Jones R, Brodsky R (2003) High dose cylcophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 48:166-173
23. Houssiau FA, D'Cruz DP, Haga H-J, Hughes GRV (1991) Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: A preliminary study. Lupus 1:1-5
24. Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, Wong RW, Lau CS (2004) Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 50:2559-2568
25. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC (2004) Treatment for lupus nephritis. Cochrane Database Syst Rev (1):CD002922
26. Williams W, Bhagwandass A, Sargeant LA, Shah D (2003) Severity of systemic lupus erythematosus with diffuse proliferative glomerulonephritis and the ineffectiveness of standard pulse intravenous cyclophosphamide therapy in Jamaican patients. Lupus 12:640-645
27. Kelly JA, Moser KL, Harley JB (2002) The genetics of systemic lupus erythematosus: Putting the pieces together. Genes Immun 3(Suppl):S71-S85
28. Petri M (2004) Cyclophosphamide: New approaches for systemic lupus erythematosus. Lupus 13:336-371
29. Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, et al (2006) Dutch working party on systemic lupus erythematosus. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 70:732-742
30. Mok CC, Ho CT, Chan KW, Lau CS, Wong RW (2002) Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 46:1003-1013
31. Sidiropoulos PI, Kritikos HD, Boumpas DT (2005) Lupus nephritis flares. Lupus 14:49-52
32. Tangnararatchakit K, Tapaneya-Olarn C, Tapaneya-Olarn W (1999) The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children. J Med Assoc Thai 82:S104-S110
33. Kang I, Park SH (2003) Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 15:528-534
34. Calguneri M, Ozbalkan Z, Ozturk MA, Apras S, Ertenli AI, Kiraz S (2006) Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome). Clin Rheumatol 25:782-788
35. Pryor BD, Bologna SG, Kahl LE (1996) Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Nephron 74:313-317
36. D'Cruz D, Cuadrado MJ, Mujic F, Tungekar MF, Taub N, Lloyd M, et al (1997) Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 15:275-282
37. Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, et al (2006) Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 119(355):e25-e33
38. Manger K, Wildt L, Kalden JR, Manger B (2006) Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: The PREGO-Study. Autoimmun Rev 5:269-272